BRAF and non-small cell lung carcinoma: We report this as the first case that demonstrates dabrafenib and trametinib can be effective and well-tolerated in patients with BRAF V600E mutated non-small cell lung cancer (NSCLC), even in those with poor performance status and acute respiratory failure. This result provides early evidence supporting the cautious use of molecular-targeted therapies in such patients.